Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to make waves in the diabetes […]
BD
BD completes spinoff of Embecta diabetes company
BD (NYSE:BDX) announced today that the planned spinoff of its diabetes business — named Embecta (Nasdaq:EMBC)— has been made official. Franklin Lakes, New Jersey-based BD announced its intention to spinoff the diabetes business in May 2021. Near the end of 2021, it unveiled the soon-to-be independent, publicly-traded company’s name as “Embecta,” with plans to complete the spinoff during the […]
Alberto Mas, president of BD’s medical segment, set to retire down this year
BD (NYSE:BDX) announced today that EVP and president of the company’s medical segment, Alberto Mas, will retire later this year. Mas, 60, informed the company of his intent to retire in a move that will be made effective at the end of BD’s fiscal year on Sept. 30, 2022. Franklin Lakes, N.J.-based BD said in […]
BD provides Embecta spinoff update, plans for April 1 completion
BD (NYSE:BDX) announced today that it still expects the spinoff of its diabetes business — named Embecta — to complete on April 1. Franklin Lakes, N.J.-based BD announced in May 2021 that it intended to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it unveiled the name of […]
BD announces cash tender offers of up to $200M
BD (NYSE:BDX) announced that Morgan Stanley commenced cash tender offers on five sets of notes worth a maximum combined purchase price of $200 million. Franklin Lakes, New Jersey-based BD said in a news release that the tender offers made by Morgan Stanley are pursuant to an offer to purchase dated March 16, 2022. The notes […]
Many infusion pumps are vulnerable to hackers, study says
Palo Alto Network’s Unit 42 released results from a study showing that 75% of infusion pumps observed had known cybersecurity gaps. The results involved crowdsourced data from scans of more than 200,000 infusion pumps on the network of health providers using IoT Security for Healthcare from Palo Alto Networks. Get the full story at our […]
BD appoints Shana Neal as chief people officer
BD (NYSE:BDX) this week announced that it appointed Shana Neal as chief people officer, effective April 4. Neal will oversee the Franklin Lakes, N.J.-based company’s human resources, communications and social investing functions globally, including talent acquisition and management; total rewards; HR operations; HR business partnering and inclusion, diversity, equity and engagement. Prior to becoming chief […]
Day Zero Diagnostics raises $21M
Infectious disease diagnostic company Day Zero Diagnostics announced today that it completed a venture equity financing worth $21 million. Sands Capital led the financing round, while significant participation came from new investors, including BD, Panacea Venture and Hongkou Capital. There was also participation from existing investors, including Triventures and Golden Seeds. To date, Zero Day […]
BD rises on Street-beating Q1, raised 2022 guidance
BD (NYSE:BDX) shares were up today on first-quarter results that came in well ahead of the consensus forecast. The Franklin Lakes, New Jersey-based company posted profits of $655 million, or $2.28 per share, on sales of $5 billion for the three months ended Dec. 31, 2021, for a 33.2% bottom-line slide on a sales decline […]
BD board approves Embecta diabetes business spinoff
BD (NYSE:BDX) announced today that its board of directors approved the planned spinoff of its diabetes care business, Embecta. Franklin Lakes, N.J.-based BD confirmed in May 2021 that it planned to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it confirmed the […]
BD acquires blood disease detection tech developer Cytognos
BD (NYSE:BDX) announced today that it completed the acquisition of flow cytometry solution developer Cytognos. Salamanca, Spain-based Cytognos specializes in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for blood diseases. Franklin Lakes, New Jersey–based BD said in a news release that the acquisition accelerates its strategy […]